The Valens Co

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Valens Groworks is a biotechnology company that specializes in cannabis extraction, testing, analytics, and manufacturing. It focused on being the partner of choice for Canadian and international cannabis brands by providing proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation, and white-label product development. The company provides diverse extraction methods to develop premium products based on their needs. The Valens Groworks seeks to capture a broad spectrum of medical cannabis users, and adult recreational users once legalized, as well as clinical trial and R&D clients, in pursuit of its ambitious seed-to-sale and farm-to-pharma objectives. The company was founded in 2010 and headquartered in Kelowna, British Columbia.

The Valens Company (TSX:VLNS, OTCQX:VLNCF) Inc announced the launch of Versus, an evolution of its Verse cannabis value brand, as well as a new ultra-premium cannabis brand, Contraband. The company said this repositioning and expansion mark the beginning of a strategic, multi-step plan to grow the Valens brand portfolio into one of the top performers in the adult recreational market.

The Valens Company launches two new cannabis brands in the value and premium markets

On Tuesday, cannabis manufacturer The Valens Company Inc. (TSX:VLNS) (NASDAQ:VLNS) confirmed the launch of Versus, an evolution of its Verse value brand. As part of the launch, the company is introducing two net new Versus product lines this week and is rebranding the full Verse portfolio this spring, for a total of approximately 20 SKUs across product categories.

The Valens Company Launches Two New Cannabis Brands Across Value And Premium Markets

Value brand 'Versus' and ultra-premium brand 'Contraband' are part of a multi-step strategy to better meet the needs of target consumers and grow the Valens adult recreational market portfolio KELOWNA, BC, Jan. 25, 2022 /PRNewswire/ - The Valens Company Inc. (TSX: VLNS) (Nasdaq: VLNS)) (the "Company" "The Valens Company" or "Valens"), a leading manufacturer of cannabis products, is pleased to announce the launch of Versus, an evolution of its Verse value brand. The launch involves the introduction of two net new Versus product lines this week, plus a rebranding of the full Verse portfolio this spring, for a total of approximately 20 SKUs across product categories.

The Valens Company Launches Two New Brands in Value and Premium Markets

The Valens Company (TSX:VLNS, OTCQX:VLNCF) Inc said its Green Roads subsidiary has announced the launch of its first-ever brand campaign "Own the Day". Valens, which is Canada's largest provider of cannabis services specializing in extraction, formulation, and product development, said the campaign celebrates Green Roads' products and their ability to help consumers with “stress, sleep, muscle and joint pain, relaxation, and focus”.

Valens Company subsidiary Green Roads launches 'Own the Day' brand campaign

KELOWNA, BC, Jan. 19, 2022 /PRNewswire/ - Green Roads, a subsidiary of The Valens Company Inc.  (TSX: VLNS) (Nasdaq: VLNS)) (the "Company" "The Valens Company" or "Valens"), announces the launch of its first-ever brand campaign "Own the Day". The campaign celebrates Green Roads' products and their ability to help consumers with common health and wellness challenges such as stress, sleep, muscle and joint pain, relaxation, and focus.

Green Roads Launches 'Own the Day' Brand Campaign

The Valens Company (TSX:VLNS, OTCQX:VLNCF) Inc has announced its highlights and achievements of 2021, while sharing details of the upcoming virtual investor day on February 7, 2022, to discuss its corporate initiatives including recent developments, financial objectives, acquisition updates for the oncoming year. “We recognize 2021 was an especially tough year for cannabis and small-cap growth investors.

The Valens Company CEO says company 'well-positioned to drive revenue growth in 2022'

The Valens Company to host virtual Investor Day on February 7, 2022 KELOWNA, BC, Jan. 18, 2022 /PRNewswire/ - The Valens Company Inc. (TSX: VLNS) (NASDAQ: VLNS) (the "Company" "The Valens Company" or "Valens"), a leading manufacturer of cannabis products, is pleased to provide a summary of key milestones and achievements made by the Company in 2021. The Company is also pleased to announce it will hold a virtual investor day on February 7, 2022 at 11:00 AM ET.

The Valens Company Reviews 2021 Milestones & Announces Virtual Investor Day

2 Marijuana Stocks To Watch Half Way Through January The post 2 Marijuana Stocks To Watch To Close Out The Second Week Of 2022 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

2 Marijuana Stocks To Watch To Close Out The Second Week Of 2022

KELOWNA, BC, Jan. 7, 2022 /PRNewswire/ - The Valens Company Inc. (TSX: VLNS) (Nasdaq: VLNS) (the "Company" "The Valens Company" or "Valens"), a leading manufacturer of cannabis products, is pleased to announce that Tyler Robson, Chief Executive Officer and Chair of The Valens Company, will participate in the ATB Capital Markets 10th Annual Institutional Investor Conference being held January 13, 2022. Management will also be participating in a day of buyside meetings.

The Valens Company to Participate in ATB Capital Markets' 10th Annual Institutional Investor Conference

BAD ETF

Canopy Growth

InMed Pharmaceuticals

Neptune Wellness Solutions Inc.

OrganiGram Holdings Inc.

Tilray Brands

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up as we round out 2021.

8 Cannabis Stocks Ablaze During Christmas Week

Cannabis producer The Valens Company Inc. (NASDAQ:VLNS) (TSX:VLNS) confirmed Wednesday that it has entered into a partnership with Montreal Cannabis Médical Inc. ("MTL") to provide manufacturing and extraction services for MTL's pre-rolls and vapes. The Kelowna, British Columbia-based marijuana said it expects the contract to begin at the end of the first quarter of fiscal 2022.

The Valens Company Teams Up With MTL Cannabis To Manufacture Pre-Rolls And Vapes

The Valens Company (TSX:VLNS, OTCQX:VLNCF) Inc said it has entered into a manufacturing partnership with Montreal Cannabis Médical Inc (MTL) to provide manufacturing and extraction services for MTL's pre-rolls and vapes. Valens noted it expects the contract to begin at the end of the first quarter of fiscal 2022.

The Valens Company partners with Montreal Cannabis Médical for extraction and manufacturing of pre-rolls and vapes

KELOWNA, BC, Dec. 22, 2021 /PRNewswire/ - The Valens Company Inc. (NASDAQ: VLNS) (TSX: VLNS) (the "Company" or "The Valens Company"), a leading manufacturer of cannabis products, announces it has entered into a manufacturing partnership with Montreal Cannabis Médical Inc. ("MTL" or "MTL Cannabis") to provide manufacturing and extraction services for MTL's pre-rolls and vapes. Valens expects the contract to begin at the end of the first quarter of fiscal 2022.

The Valens Company Enters Manufacturing Partnership with MTL Cannabis for Extraction and Manufacturing of Pre-rolls and Vapes

The Valens Company (TSX:VLNS, OTCQX:VLNCF) Inc announced two new agreements with PMI Mexico to supply CBD for the pharmaceutical company's pharmacokinetic (PK) stage medical trials.  PMI Mexico, a subsidiary of Merger Group, is one of the main drug suppliers to the Mexican government, according to Valens.

The Valens Company inks two agreements with PMI Mexico, one of the leading drug suppliers to the Mexican government

The Valens Company Inc. (TSX:VLNS) (NASDAQ:VLNS) confirmed Tuesday it had entered into two agreements with PMI Mexico, a subsidiary of Merger Group, one of the main drug suppliers of the Mexican government. "The relationship we have built with PMI Mexico marks an important milestone for Valens' international expansion and the beginning of our Central and Latin America strategy," Tyler Robson, CEO, chair & co-founder of The Valens Company stated.

Valens Company Signs Agreements With Mexican Drug Supplier To Provide CBD Oil And Prebiotic Products

•  Valens to serve as exclusive supplier of CBD for PMI's clinical trial, which will measure   anti-inflammatory applications of medical-grade, nano-water emulsified CBD oil • Valens will manufacture and distribute CBD infused and uninfused Predilife Ⓡ  prebiotic products for PMI throughout the country  KELOWNA, BC, Dec. 21, 2021 /PRNewswire/ -   The Valens Company Inc. (TSX: VLNS) (NASDAQ: VLNS) (the "Company," "The Valens Company" or "Valens"), a leading manufacturer of cannabis products, announced today two agreements with PM I Mexico , a subsidiary of Merger Group, one of the main drug suppliers of the Mexican government. Under the first agreement, Valens will supply CBD for PMI's ongoing pharmacokinetic (PK) stage medical trials, which are focused on anti-inflammatory applications of medical-grade, nano-water emulsified CBD oil.

The Valens Company Announces Two Strategic Agreements with PMI Mexico

Stifel GMP has repeated its 'Buy' rating on The Valens Company as it thinks the company's profile "risk-reward seems appealing now". In a note to clients, the broker's analysts noted that Valens recently announced a $40 million debt financing at 10% to shore up its balance sheet with non-dilutive capital and refinance existing debt.

Stifel GMP repeats 'Buy' on The Valens Company as it thinks "risk-reward seems appealing now"

The Valens Company (TSX:VLNS, OTCQX:VLNCF) Inc, a leading manufacturer of cannabis products, told investors it has entered into a secured non-revolving term loan with 2361380 Ontario Limited, a private institutional lender, for an aggregate principal amount up to C$40 million. The Kelowna-based company said the loan will be used to further strengthen its balance sheet, allowing it to execute on its corporate strategy and fund working capital needs as the business continues its aggressive growth trajectory, as well as immediately retire the remaining $7.5 million outstanding under its existing debt facility.

The Valens Company secures C$40M term loan to support “aggressive growth strategy”

Cannabis manufacturer The Valens Company Inc. (TSX: VLNS) (NASDAQ: VLNS) will borrow CA$40 million ($31.3 million) from a private institutional lender. The company, based in  Kelowna, British Columbia-based, confirmed on Thursday it has entered into a secured non-revolving term loan with 2361380 Ontario Limited.

The Valens Company Borrows $31.3M To Retire Its Debt And Strengthen Balance Sheet

Non-dilutive debt capital provides Valens with greater flexibility in its growth strategy in Canada and United States KELOWNA, BC, Dec. 16, 2021 /PRNewswire/ - The Valens Company Inc. (TSX: VLNS) (Nasdaq: VLNS) (the "Company" "The Valens Company" or "Valens"), a leading manufacturer of cannabis products, announces that it has entered into a secured non-revolving term loan (the "Loan Agreement") with 2361380 Ontario Limited , a private institutional lender, for an aggregate principal amount up to CAD$40 million (the "Loan"). The Loan will accrue interest at a rate of 10% per annum, payable quarterly, and matures on December 15, 2023 with an initial interest payment date on December 31, 2021.

The Valens Company Secures CAD$40 Million Term Loan

Agrify

Flora Growth Corp

GrowGeneration Corp

High Tide

India Globalization Capital

Jupiter Wellness

Chicago Atlantic Real Estate Finance

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

9 Hottest Stories from the Cannabis Sector This Week

The Valens Company Inc. VLNS, +3.37% VLNS, +3.37% said its common shares will start trading on the Nasdaq Capital Market as of Thursday. Valens CEO Tyler Robson said the listing marks an "important milestone" for the company.

Canadian cannabis company Valens debuts shares on Nasdaq

Common Shares are Now Trading Under the Ticker "VLNS" KELOWNA, BC, Dec. 9, 2021 /PRNewswire/ -  The Valens Company Inc.  (TSX: VLNS) (NASDAQ: VLNS) (the "Company" "The Valens Company" or "Valens"), a leading manufacturer of cannabis products, announces that the Company's common shares have commenced trading on Nasdaq Capital Market ("Nasdaq") as of market open today, December 9, 2021. Shareholders are not required to take any action as a result of the up-listing and symbol change.

News for The Valens Co Stock (VLNS)